| Campo DC | Valor | Idioma |
|---|
| dc.contributor.author | Sampaio, Raimunda Nonata Ribeiro | pt_BR |
| dc.contributor.author | Silva, Juliana Saboia Fontenele e | pt_BR |
| dc.contributor.author | Paula, Carmen Dea Ribeiro de | pt_BR |
| dc.contributor.author | Porto, Cláudia | pt_BR |
| dc.contributor.author | Motta, Jorgeth de Oliveira Carneiro da | pt_BR |
| dc.contributor.author | Pereira, Ledice Inacia de Araujo | pt_BR |
| dc.contributor.author | Martins, Sofia Sales | pt_BR |
| dc.contributor.author | Barroso, Daniel Holanda | pt_BR |
| dc.contributor.author | Freire, Gustavo Subtil Magalhães | pt_BR |
| dc.contributor.author | Gomes, Ciro Martins | pt_BR |
| dc.date.accessioned | 2020-01-24T10:29:59Z | - |
| dc.date.available | 2020-01-24T10:29:59Z | - |
| dc.date.issued | 2019 | pt_BR |
| dc.identifier.citation | SAMPAIO, Raimunda Nonata Ribeiro et al. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical. v. 52, e20180292, 2019. DOI: https://doi.org/10.1590/0037-8682-0292-2018. Disponível em: http://scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822019000100315. Acesso em: 23 janeiro 2020. | pt_BR |
| dc.identifier.uri | https://repositorio.unb.br/handle/10482/36245 | - |
| dc.language.iso | en | pt_BR |
| dc.publisher | Sociedade Brasileira de Medicina Tropical - SBMT | pt_BR |
| dc.rights | Acesso Aberto | pt_BR |
| dc.title | A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis | pt_BR |
| dc.type | Artigo | pt_BR |
| dc.subject.keyword | Leishmaniose | pt_BR |
| dc.subject.keyword | Leishmaniose tegumentar americana | pt_BR |
| dc.subject.keyword | Ensaios clínicos | pt_BR |
| dc.subject.keyword | Terapêutica | pt_BR |
| dc.subject.keyword | Medicamentos | pt_BR |
| dc.rights.license | OPEN ACCESS - https://creativecommons.org/licenses/by/4.0/. (CC BY). | - |
| dc.identifier.doi | https://doi.org/10.1590/0037-8682-0292-2018 | pt_BR |
| dc.description.abstract1 | INTRODUCTION: The treatment of mucosal leishmaniasis (ML) is difficult due to the toxicity and route of administration of standard drugs. Miltefosine is an oral agent used for leishmaniasis treatment; however, no data exist regarding its use for ML in Brazil. In this study, we aimed to evaluate the efficacy of miltefosine for ML treatment compared to that of pentavalent antimonial in a pilot study. METHODS: We performed a randomized clinical trial with two parallel groups. The tested intervention consisted of miltefosine 1.3-2 mg/kg/day (two capsules) for 28 days or intravenous 20 mg SbV/kg/day of meglumine antimoniate (N-MA) for 30 days. The final endpoint was defined as complete healing of the lesion four years after treatment. We also analyzed an early endpoint at 90 days after treatment. RESULTS: Forty patients were included in this study: each experimental group comprised 20 patients. Applying a multivariate model in an intention-to-treat analysis, we observed that patients treated with miltefosine had a cure probability 2.08 times greater (95% confidence interval [CI] = 1.03-4.18) than those treated with N-MA at 90 days after treatment. At the final endpoint, we observed no differences in cure probability between miltefosine and N-MA (relative risk = 0.66; 95% CI = 0.33-1.32). With respect to adverse reactions, significant differences between groups were related to gastrointestinal effects, which were more frequent in the miltefosine group. CONCLUSIONS: Miltefosine may be an interesting alternative for treating ML because of its oral administration and cure rate after long-term follow-up. | - |
| dc.identifier.orcid | http://orcid.org/0000-0002-8223-0058 | - |
| dc.description.unidade | Faculdade de Medicina (FMD) | - |
| Aparece nas coleções: | Artigos publicados em periódicos e afins
|
